Thursday, June 13, 2024


Dhaka Tribune

New HIV vaccine shows promise in first-in-human trial

Phase 1 trials of the vaccine showed 97% of the people in the trials were able to create the broad antibodies needed to combat HIV

Update : 07 Apr 2021, 06:00 PM

A new vaccine for the HIV showed promise in its preliminary trials, and could potentially be the first step to a multi-step vaccine that could possibly prevent the HIV.

The HIV, or human immunodeficiency virus, is the virus that causes Acquired Immunodeficiency Syndrome (AIDS), ABC News reported.

The initial data from a clinical trial from the International AIDS Vaccine Initiative and The Scripps Research Institute in California shows that it might hold promise.

Dr William Schaffner, a professor of preventive medicine and infectious diseases at Vanderbilt University in Nashville said: "These are very early studies. But nonetheless, they are provocative.”

This vaccine is a milestone when it comes to the research in alleviating HIV, and is supported by the mRNA methods that are also seen in the Moderna and Pfizer Covid-19 vaccines.

The initial news about the trials was reported in February by Scripps Research, however over the last few days, the trial has gone viral on social media.

The vaccine will, however, need to be tested in studies that are much larger in order to prove the effectiveness.

Experts are hopeful that this vaccine may be more successful compared to others in research in the past.

"This is a very innovative approach to developing a vaccine that hasn't been done before," Schaffner added, describing the vaccine as a "kind of a culmination of 21st century science."

HIV usually mutates often, which is problematic when it comes to developing vaccines for it. It also has different types within itself, so not all vaccines that are developed will be effective against every type.

The research by Scripps and IAVI targets these problems by developing a vaccine that create neutralizing antibodies.

The researchers in the organizations would like for the vaccine to prompt a person's immune system to fight against HIV variants and mutations.

Phase 1 of the clinical trial included 48 participants who received 2 doses of the vaccine or placebo each, with a gap of 2 months.

Results from the preliminary trial showed that 97% of the people who received the vaccine had evidence that the immune system in their bodies were able to create the broad antibodies needed to combat HIV.

The new vaccine is not based on the Moderna vaccine; however, the parent company Scripps is partnering with Moderna for developments in the future.

The mRNA method’s success with the Covid-19 vaccine indicates that it could be explored by scientists to potentially create solutions for other diseases.

Top Brokers


Popular Links